Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium

International Journal of Cancer

Volumn 136, Issue 5, 2015, Pages E410-E422

  Felix, Ashley S ^a   Gaudet, Mia M ^b   La Vecchia, Carlo ^c   Nagle, Christina M ^d   Shu, Xiao Ou ^e   Weiderpass, Elisabete ^f,g,h,i   Adami, Hans Olov ^f,j   Beresford, Shirley ^k   Bernstein, Leslie ^l   Chen, Chu ^k   Cook, Linda S ^m   De Vivo, Immaculata ^j,n   Doherty, Jennifer A ^k,o   Friedenreich, Christine M ^p   Gapstur, Susan M ^b   Hill, Dierdre ^k   Horn Ross, Pamela L ^q   Lacey, James V ^l   Levi, Fabio ^r   Liang, Xiaolin ^s   Lu, Lingeng ^t   Magliocco, Anthony ^u   McCann, Susan E ^v   Negri, Eva ^w   Olson, Sara H ^s   Palmer, Julie R ^x   Patel, Alpa V ^b   Petruzella, Stacey ^s   Prescott, Jennifer ^j,n   Risch, Harvey A ^t   Rosenberg, Lynn ^x   Sherman, Mark E ^a   Spurdle, Amanda B ^d   Webb, Penelope M ^d   Wise, Lauren A ^x   Xiang, Yong Bing ^y   Xu, Wanghong ^z   Yang, Hannah P ^a   Yu, Herbert ^aa   Zeleniuch Jacquotte, Anne ^ab   Brinton, Louise A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g CANCER REGISTRY OF NORWAY   (Norway)

^h UNIVERSITY OF TROMSØ   (Norway)

ⁱ FOLKHÄLSAN RESEARCH CENTER   (Finland)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^k Fred Hutchinson Cancer Research Center   (United States)

^l CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^m UNIVERSITY OF NEW MEXICO   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o DARTMOUTH MEDICAL SCHOOL   (United States)

^p ALBERTA HEALTH SERVICES   (Canada)

^q CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^r UNIVERSITY OF LAUSANNE   (Switzerland)

^s MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^t YALE UNIVERSITY   (United States)

^u H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^v ROSWELL PARK CANCER INSTITUTE   (United States)

^w MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^x BOSTON UNIVERSITY   (United States)

^y SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^z FUDAN UNIVERSITY   (China)

^aa UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^ab NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Contraception; Endometrial neoplasm; Etiology; Pooled analysis

Indexed keywords

ADULT; AGE; ARTICLE; BODY MASS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; COPPER INTRAUTERINE DEVICE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; HORMONAL THERAPY; HORMONE RELEASING INTRAUTERINE DEVICE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; ORAL CONTRACEPTIVE USE; PARITY; POSTMENOPAUSE; PREVALENCE; RISK REDUCTION; SMOKING; TREATMENT DURATION; ADVERSE EFFECTS; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTRACEPTION; ENDOMETRIAL NEOPLASMS; FOLLOW UP; META ANALYSIS (TOPIC); MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UNITED STATES; UTILIZATION;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; CONTRACEPTION; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAUTERINE DEVICES; META-ANALYSIS AS TOPIC; MIDDLE AGED; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 84918828502     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29229     Document Type: Article

References (76)

1. Beining RM, Dennis LK, Smith EM, et al. Metaanalysis of intrauterine device use and risk of endometrial cancer. Ann Epidemiol 2008;18:492-9.
2. Thiery M. Pioneers of the intrauterine device. Eur J Contracept Reprod Health Care 1997;2:15-23.
3. Hubacher D, Cheng D. Intrauterine devices and reproductive health: American women in feast and famine. Contraception 2004;69:437-46.
4. Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397-404.
5. Group ECW. Intrauterine devices and intrauterine systems. Hum Reprod Update 2008;14:197-208.
6. Mishell DR, Jr. Intrauterine devices: mechanisms of action, safety, and efficacy. Contraception 1998;58:45S-53S; quiz 70S.
7. Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 2007;75:S16-30.
8. Tursi A, Mastrorilli A, Ribatti D, et al. Possible role of mast cells in the mechanism of action of intrauterine contraceptive devices. Am J Obstet Gynecol 1984;148:1064-6.
9. Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. Am J Obstet Gynecol 2002;187:1699-708.
10. Guttinger A, Critchley HO. Endometrial effects of intrauterine levonorgestrel. Contraception 2007;75:S93-8.
11. Ammala M, Nyman T, Strengell L, et al. Effect of intrauterine contraceptive devices on cytokine messenger ribonucleic acid expression in the human endometrium. Fertil Steril 1995;63:773-8.
12. Moyer DL, Mishell DR, Jr. Reactions of human endometrium to the intrauterine foreign body. II. Long term effects on the endometrial histology and cytology. Am J Obstet Gynecol 1971;111:66-80.
13. Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices. Contraception 2007;75:S60-9.
14. Shu XO, Brinton LA, Zheng W, et al. A population-based case-control study of endometrial cancer in Shanghai, China. Int J Cancer 1991;49:38-43.
15. Castellsague X, Thompson WD, Dubrow R. Intra-uterine contraception and the risk of endometrial cancer. Int J Cancer 1993;54:911-6.
16. Parazzini F, La Vecchia C, Moroni S. Intrauterine device use and risk of endometrial cancer. Br J Cancer 1994;70:672-3.
17. Rosenblatt KA, Thomas DB. Intrauterine devices and endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception 1996;54:329-32.
18. Sturgeon SR, Brinton LA, Berman ML, et al. Intrauterine device use and endometrial cancer risk. Int J Epidemiol 1997;26:496-500.
19. Hill DA, Weiss NS, Voigt LF, et al. Endometrial cancer in relation to intra-uterine device use. Int J Cancer 1997;70:278-81.
20. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, et al. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 1999;59:3658-62.
21. Benshushan A, Paltiel O, Rojansky N, et al. IUD use and the risk of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2002;105:166-9.
22. Tao MH, Xu WH, Zheng W, et al. Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. Int J Cancer 2006;119:2142-7.
23. Wernli KJ, Ray RM, Gao DL, et al. Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women. Cancer Causes Control 2006;17:949-55.
24. Xu X, Macaluso M, Ouyang L, et al. Revival of the intrauterine device: increased insertions among US women with employer-sponsored insurance, 2002-2008. Contraception 2012;85:155-9.
25. Olson SH, Chen C, De Vivo I, et al. Maximizing resources to study an uncommon cancer: E2C2-Epidemiology of Endometrial Cancer Consortium. Cancer Causes Control 2009;20:491-6.
26. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 2002;94:2490-501.
27. Karageorgi S, Hankinson SE, Kraft P, et al. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer 2010;126:208-16.
28. Kumle M, Weiderpass E, Braaten T, et al. Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002;11:1375-81.
29. Rosenberg L, Adams-Campbell L, Palmer JR. The Black Women's Health Study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc 1995;50:56-8.
30. Bernstein L, Allen M, Anton-Culver H, et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 2002;13:625-35.
31. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
32. McCann SE, Freudenheim JL, Marshall JR, et al. Diet in the epidemiology of endometrial cancer in western New York (United States). Cancer Causes Control 2000;11:965-74.
33. La Vecchia C, Franceschi S, Gallus G, et al. Oestrogens and obesity as risk factors for endometrial cancer in Italy. Int J Epidemiol 1982;11:120-6.
34. Negri E, La Vecchia C, Franceschi S, et al. Intake of selected micronutrients and the risk of endometrial carcinoma. Cancer 1996;77:917-23.
35. Levi F, La Vecchia C, Gulie C, et al. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. Eur J Cancer 1993;29A: 1445-9.
36. Arem H, Irwin ML, Zhou Y, et al. Physical activity and endometrial cancer in a population-based case-control study. Cancer Causes Control 2011;22:219-26.
37. Olson SH, Orlow I, Bayuga S, et al. Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control 2008;19:955-63.
38. Hill DA, Weiss NS, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456-61.
39. Bodelon C, Doherty JA, Chen C, et al. Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol 2009;170:1512-7.
40. Friedenreich CM, Cook LS, Magliocco AM, et al. Case-control study of lifetime total physical activity and endometrial cancer risk. Cancer Causes Control 2010;21:1105-16.
41. Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 1992;167:1317-25.
42. Neill AS, Nagle CM, Spurdle AB, et al. Use of talcum powder and endometrial cancer risk. Cancer Causes Control 2012;23:513-9.
43. Xu WH, Shrubsole MJ, Xiang YB, et al. Dietary folate intake, MTHFR genetic polymorphisms, and the risk of endometrial cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2007;16:281-7.
44. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013.
45. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
46. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
47. Thompson SG, Higgins JP. How should metaregression analyses be undertaken and interpreted? Statistics Med 2002;21:1559-73.
48. Soini T, Hurskainen R, Grenman S, et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014;124:292-9.
49. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.
50. Henderson BE, Ross RK, Pike MC, et al. Endogenous hormones as a major factor in human cancer. Cancer Res 1982;42:3232-9.
51. Hefnawi F, Segal SJ, Council P. Analysis of intrauterine contraception: proceedings of the third international conference on intrauterine contraception, Cairo, Arab Republic of Egypt, 12-14 December 1974. Amsterdam: North-Holland Pub. Co., 1975.
52. De Castro A, Gonzalez-Gancedo P, Contreras F, et al. The effect of copper ions in vivo on specific hormonal endometrial receptors. Adv Contraception 1986;2:399-404.
53. Punnonen R, Pettersson K, Vanharanta R. Androgen, estrogen and progestin cytosol receptor concentrations in the normal human endometrium. Effects of intrauterine device. Gynecol Obstet Invest 1984;17:73-7.
54. Guleria K, Agarwal N, Mishra K, et al. Evaluation of endometrial steroid receptors and cell mitotic activity in women using copper intrauterine device: can Cu-T prevent endometrial cancer? J Obstet Gynaecol Res 2004;30:181-7.
55. Janne O, Ylostalo P. Endometrial estrogen and progestin receptors in women bearing a progesterone-releasing intrauterine device. Contraception 1980;22:19-23.
56. Critchley HO, Wang H, Kelly RW, et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod 1998;13:1210-7.
57. Zhu P, Liu X, Luo H, et al. The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use. Hum Reprod 1999;14:970-5.
58. Vereide AB, Kaino T, Sager G, et al. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 2006;101:214-23.
59. Hurskainen R, Salmi A, Paavonen J, et al. Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel. Mol Hum Reprod 2000;6:1013-8.
60. Salmi A, Pakarinen P, Peltola AM, et al. The effect of intrauterine levonorgestrel use on the expression of c-JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium. Mol Hum Reprod 1998;4:1110-5.
61. Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984;41:52-5.
62. Xiao B, Zeng T, Wu S, et al. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception 1995;51:359-65.
63. Shalev E, Harpaz-Kerpel S, Engelhard Y, et al. Serum ovarian steroids, prolactin and prostaglandin metabolites in women using the inert intrauterine device. Int J Gynaecol Obstet 1987;25:139-44.
64. Brenner PF, Mishell DR, Jr. Progesterone and estradiol patterns in women using an intrauterine contraceptive device. Obstet Gynecol 1975;46:456-9.
65. Guillebaud J, Bonnar J, Morehead J, et al. Menstrual blood-loss with intrauterine devices. Lancet 1976;1:387-90.
66. Heikkila M, Nylander P, Luukkainen T. Body iron stores and patterns of bleeding after insertion of a levonorgestrel- or a copper-releasing intrauterine contraceptive device. Contraception 1982;26:465-74.
67. Andrade AT, Pizarro Orchard E. Quantitative studies on menstrual blood loss in IUD users. Contraception 1987;36:129-44.
68. Andersson K, Odlind V, Rybo G. Levonorgestrelreleasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.
69. Rana M, Saxena P, Firdous N. Comparison of levonorgestrel and copper releasing intrauterine contraceptive device on body iron stores and menstrual bleeding patterns: experience on Indian women. Eur Rev Med Pharmacol Sci 2012;16:230-4.
70. Milsom I, Andersson K, Jonasson K, et al. The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status. Contraception 1995;52:175-9.
71. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012;22:33-40.
72. Modugno F, Ness RB, Chen C, et al. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev 2005;14:2840-7.
73. Schonfeld SJ, Hartge P, Pfeiffer RM, et al. An aggregated analysis of hormonal factors and endometrial cancer risk by parity. Cancer 2013;119:1393-401.
74. Pfeiffer RM, Mitani A, Landgren O, et al. Timing of births and endometrial cancer risk in Swedish women. Cancer Causes Control 2009;20:1441-9.
75. Brinton LA, Sakoda LC, Lissowska J, et al. Reproductive risk factors for endometrial cancer among Polish women. Br J Cancer 2007;96:1450-6.
76. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 2007;25:5158-64.